Clinical trial · Interventional
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis
NCT02867033CI-TRIAL-00106813ALTITUDESactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aggressive Fibromatosis | Desmoid Fibromatosis | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biobank constitution | Other | — | UNRESOLVED |
| biopsy | Procedure | — | UNRESOLVED |
| Blood sampling (facultative) | Procedure | — | UNRESOLVED |
| Coloscopy | Procedure | — | UNRESOLVED |
| Pain evaluation | Other | — | UNRESOLVED |
| Tumor biobank realization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Study procedure
- description
- Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
- interventionNames
- Procedure: biopsy
- Other: biobank constitution
- Procedure: Coloscopy
- Procedure: Blood sampling (facultative)
- Other: Pain evaluation
- Procedure: Tumor biobank realization
Primary outcomes (1)
- measure
- Incident cases of aggressive fibromatosis, diagnosed after 01/01/2016 in France
- timeFrame
- through study completion, an average of 5 years
- description
- To constitute, at a national level, the largest cohort of incident cases of desmoid tumours
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Incident Case of aggressive fibromatosis in France, diagnosed after 01/01/2016 * Confirmed diagnosis by the French anatomopathological diagnosis network (including search for mutation of the β-Catenin Gene, CTNNB1) * Affiliation to the National Health System * Informed consent signed (both parents signature for non adult patients) Exclusion Criteria: * Administrative or legal measure of liberty privation * Patient not able to give consent or unwilling to provide consent
References
Publications (1)
- DERIVEDPenel N, Bonvalot S, Bimbai AM, Meurgey A, Le Loarer F, Salas S, Piperno-Neumann S, Chevreau C, Boudou-Rouquette P, Dubray-Longeras P, Kurtz JE, Guillemet C, Bompas E, Italiano A, Le Cesne A, Orbach D, Thery J, Le Deley MC, Blay JY, Mir O. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis. Clin Cancer Res. 2022 Sep 15;28(18):4105-4111. doi: 10.1158/1078-0432.CCR-21-4235. PMID 35294527